Skip to main content
CRIS
NASDAQ Life Sciences

Curis Schedules Shareholder Vote on Reverse Stock Split to Avoid Nasdaq Delisting

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.499
Mkt Cap
$19.489M
52W Low
$0.464
52W High
$3.13
Market data snapshot near publication time

Summary

Curis Inc. has filed a definitive proxy statement scheduling a special meeting on June 25, 2026, for shareholders to vote on a reverse stock split, a measure aimed at increasing its share price to meet Nasdaq's listing requirements and prevent delisting.


Key Events

  • Special Shareholder Meeting Scheduled

    A special meeting will be held on June 25, 2026, for stockholders to vote on a reverse stock split proposal.

  • Reverse Stock Split Proposal

    The Board seeks approval for amendments to its charter to effect a reverse stock split with a ratio ranging from 1-for-5 to 1-for-25, at the Board's discretion.

  • Nasdaq Delisting Threat

    The primary reason for the reverse split is to increase the stock price to meet Nasdaq's minimum $1.00 bid price requirement, following a delisting determination letter received on April 27, 2026.

  • Financial Distress Context

    This proposal follows recent disclosures of 'going concern' doubt and significant net losses, highlighting the company's precarious financial position.


Analysis

This definitive proxy statement formalizes the company's plan to implement a reverse stock split, a critical step in its effort to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. The company previously received a delisting determination letter from Nasdaq and has disclosed substantial doubt about its ability to continue as a going concern. While a reverse split does not change the company's intrinsic value, it is a necessary defensive measure to maintain its exchange listing, which is vital for liquidity and investor confidence, especially for a company in financial distress.

At the time of this filing, CRIS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.46 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRIS - Latest Insights

CRIS
Jun 05, 2026, 9:06 AM EDT
Filing Type: DEF 14A
Importance Score:
9
CRIS
May 22, 2026, 5:05 PM EDT
Filing Type: PRE 14A
Importance Score:
9
CRIS
May 22, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
May 13, 2026, 9:20 AM EDT
Filing Type: 10-Q
Importance Score:
9
CRIS
May 12, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
May 12, 2026, 4:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
CRIS
May 01, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
CRIS
May 01, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
Apr 21, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
9
CRIS
Apr 10, 2026, 4:19 PM EDT
Filing Type: PRE 14A
Importance Score:
9